Brief: Essa Pharma Announces Initiation Of Phase 2 Study Evaluating Masofaniten In Combination With Enzalutamide In Patients With A Type Of Prostate Cancer
18/09/2023 12:13
Sept 18 (Reuters) - ESSA Pharma Inc EPIX.O :
* ESSA PHARMA ANNOUNCES INITIATION OF PHASE 2 STUDY
EVALUATING
MASOFANITEN (EPI-7386) IN COMBINATION WITH ENZALUTAMIDE IN
PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
* ESSA PHARMA INC - PHASE 2 HEAD-TO-HEAD PORTION OF STUDY TO
COMMENCE ENROLLMENT IMMEDIATELY
Source text for Eikon: ID:nPn8FxgrFa
Further company coverage: EPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ESSA Pharma
See all newsBrief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: ESSA Pharma Provides Update On Its Application To The Supreme Court Of British Columbia For Amended Interim Order
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics